Kymera Therapeutics, Inc.
KYMR
$65.99
$1.722.68%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.26% | -16.82% | 7.31% | -13.23% | -48.56% |
| Total Depreciation and Amortization | 3.12% | 1.76% | 3.07% | 0.00% | 2.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 31.40% | 13.55% | 11.17% | -6.64% | 9.31% |
| Change in Net Operating Assets | 2,523.76% | 104.94% | -669.50% | -265.71% | 92.61% |
| Cash from Operations | 54.73% | 24.34% | -28.11% | -23.10% | -16.89% |
| Capital Expenditure | 73.96% | -48.82% | 50.11% | -595.24% | 104.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -487.24% | 23.70% | -29.38% | 144.03% | -876.49% |
| Cash from Investing | -492.03% | 23.46% | -29.10% | 143.49% | -1,108.06% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -9.69% | -37.91% | 5.46% | 54.29% | -82.10% |
| Issuance of Common Stock | -83.78% | 45,901.50% | -98.30% | -87.51% | 14,160.71% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -83.92% | 95,142.64% | -90.67% | -98.90% | 17,670.40% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -190.66% | 912.05% | -417.07% | -77.82% | 266.32% |